Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncolys BioPharmaTSE:4588 +17.03%39 PB Ratio is 43.26 as of Aug. 29, 2026, which is 594% above its 10-year median of 6.23. GuruFocus rates TSE:4588 with a GF Score™ of 39/100 and a GF Value™ of 円353.08 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,213 Biotechnology companies, Oncolys BioPharma ranks worse than 96.54% on this metric.
Oncolys BioPharma Inc stock PB Ratio (=30.4) is close to 10-year high of 30.4.
The historical rank and industry rank for Oncolys BioPharma's PB Ratio or its related term are showing as below:
TSE:4588'
s PB Ratio Range Over the Past 10 Years
Min: 2.12 Med: 6.23 Max: 43.27
Current: 43.27
During the past 13 years, Oncolys BioPharma's highest PB Ratio was 43.27. The lowest was 2.12. And the median was 6.23.
TSE:4588's PB Ratio is ranked worse than 96.54% of 1213
companies
in the Biotechnology industry
Industry Median: 2.95
vs TSE:4588: 43.27
During the past 12 months, Oncolys BioPharma's average Book Value Per Share Growth Rate was 42.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 3.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -6.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -11.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Oncolys BioPharma was 94.20% per year. The lowest was -20.40% per year. And the median was -17.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Oncolys BioPharma PB Ratio Related Terms
Oncolys BioPharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Oncolys BioPharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oncolys BioPharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncolys BioPharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncolys BioPharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Oncolys BioPharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Oncolys BioPharma (TSE:4588) has a PB Ratio of 43.26 as of Aug. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Oncolys BioPharma and its competitors. This is 594% above median its historical median of 6.23. Over the past decade, Oncolys BioPharma's PB Ratio has ranged from 2.12 to 43.27. According to the industry distribution chart, Oncolys BioPharma ranks #1171 out of 1213 companies in the Biotechnology industry, placing it in the top 96.5%.
Is Oncolys BioPharma's PB Ratio too high?
Oncolys BioPharma's current PB Ratio of 43.26 is 594% above median its 10-year median of 6.23. Over the past 10 years, this metric has ranged from a low of 2.12 to a high of 43.27. The Biotechnology industry median PB Ratio is 2.95. Oncolys BioPharma's value of 43.26 is 1366.4% above this industry median. Based on the distribution chart, Oncolys BioPharma ranks #1171 out of 1213 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncolys BioPharma has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncolys BioPharma ranks #1171 out of 1213 companies for PB Ratio. This places Oncolys BioPharma in the lower half of its industry. The industry median PB Ratio is 2.95. Oncolys BioPharma's value of 43.26 is 1366.4% above this benchmark. Historically, Oncolys BioPharma's own PB Ratio has ranged from 2.12 to 43.27 over the past decade. While the company's 10-year median is 6.23 vs. the industry median of 2.95, Oncolys BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,213 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncolys BioPharma's current PB Ratio of 43.26 is 1366.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Oncolys BioPharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncolys BioPharma's current PB Ratio is 43.26, which is 594% above median its own 10-year median of 6.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円353.08, compared to a current price of 円4,810.00 — trading 1262.3% above its estimated fair value. The current PB Ratio is 43.26, which is 594% above median its 10-year median of 6.23 and 1366.4% above the Biotechnology industry median of 2.95. Oncolys BioPharma's overall GF Score™ is 39/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current PB Ratio is 43.26 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?
Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued.
The current stock price of 円4,810.00 is trading 1262.3% above its estimated GF Value™ of 円353.08.
GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.
Key valuation signals for TSE:4588:
PB Ratio: 43.26 (594% above median its 10-year median of 6.23)
GF Value™: 円353.08 vs. price of 円4,810.00 (1262.3% above fair value)
Industry Position: 1366.4% above the Biotechnology median (#1171 of 1213)
No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
39GF Score
Get the complete analysis for TSE:4588
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4588 has been successfully added to your 
